Recommendations from the national multiple sclerosis society clinical outcomes assessment task force
暂无分享,去创建一个
Christian Confavreux | John Petkau | Karl Syndulko | Jack Antel | Aaron Miller | S. Reingold | F. Lublin | J. Fischer | R. Rudick | E. Willoughby | B. Weinshenker | J. Petkau | K. Syndulko | J. Antel | C. Confavreux | G. Ellison | Fred Lublin | Alan Thompson | Richard Rudick | Jill Fischer | Gary Cutter | George Ellison | Stephen Rao | Stephen Reingold | Joy Wallenberg | Brian Weinshenker | Ernest Willoughby | G. Cutter | Alan Thompson | Aaron Miller | Joy Wallenberg | S. Rao
[1] Christian Confavreux,et al. Clinical outcomes assessment in multiple sclerosis , 1996, Annals of neurology.
[2] D. Gronwall. Paced Auditory Serial-Addition Task: A Measure of Recovery from Concussion , 1977, Perceptual and motor skills.
[3] H. Weiner,et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. , 1983, The New England journal of medicine.
[4] K. Syndulko,et al. Comparative evaluations of neuroperformance and clinical outcome assessments in chronic progressive multiple sclerosis: I. reliability, validity and sensitivity to disease progression , 1996, Multiple sclerosis.
[5] D. Wolinsky,et al. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: A randomized, double‐blinded, placebo‐controlled clinical trial , 1990 .
[6] H. McFarland,et al. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis , 1995, Multiple sclerosis.
[7] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[8] R. Knobler,et al. A neurologic rating scale (NRS) for use in multiple sclerosis , 1984, Neurology.
[9] D. Goodkin,et al. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. , 1988, Archives of physical medicine and rehabilitation.
[10] M. R. Mickey,et al. A placebo‐controlled, randomized, double‐masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis , 1989, Neurology.
[11] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[12] C. Goldsmith,et al. Interpretation and power of a pooled index. , 1993, The Journal of rheumatology.
[13] S. Medendorp,et al. Low‐dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis , 1995, Annals of neurology.